DaVita Crushes Q1, Boosts Guidance

DaVitas Q1 results exceed expectations, with adjusted operating income guidance raised to $2.15-2.25 billion and adjusted earnings per share to $14.10-$15.20. Volume growth is now projected at 25-50 basis points, driven by lower mortality and patient transfers. Integrated Kidney Care excels in the governments Comprehensive Kidney Care Contracting program, with strong labor productivity. DaVita invests in AI for staffing and scheduling, and ACA plan enrollment trends better than expected. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b38aedd2d5baf8c7